| abstract |
The disclosure provides a method of treating or ameliorating a disease or disorder by an oral cytidine analog (e. G. 5-azacytidine) in combination with an anti-PD1 / anti-PDL1 antibody (e. G., Fembrerizumab or more valmab) . ≪ / RTI > The disease or disorder includes, but is not limited to, recurrent or refractory myelodysplastic syndrome, acute myelogenous leukemia, ovarian cancer or non-small cell lung cancer. |